ASCO/CAP |
American Society of Clinical Oncology/College of American Pathologists |
|
ACOSOG |
American College of Surgeons Oncology Group |
|
ACR |
American College of Radiology |
米国放射線専門医会 |
ALND |
axillary lymph node dissection |
腋窩リンパ節郭清 |
AOR |
annual odds of recurrence |
年間再発率 |
APBI |
accelerated partial breast irradiation |
加速乳房部分照射 |
ASA |
American Society of Anesthesiologists |
米国麻酔科学会 |
ASCO |
American Society of Clinical Oncology |
米国臨床腫瘍学会 |
ASTRO |
American Society for Radiation Oncology |
米国放射線腫瘍学会 |
BMD |
bone mineral density |
骨密度 |
BMI |
body mass index |
|
BOOP |
bronchiolitis obliterans organizing pneumonia |
|
CALGB |
Cancer and Leukemia Group B |
|
CAM |
complementary and alternative medicine |
補完・代替療法 |
CBR |
clinical benefit rate |
クリニカルベネフィット率 |
CI |
confidence interval |
信頼区間 |
CIA |
chemotherapy‒induced amenorrhea |
化学療法誘発性無月経 |
CR |
complete response |
完全奏効 |
CTV |
clinical target volume |
臨床標的体積 |
DBCG |
Danish Breast Cancer Cooperative Group |
|
DCIS |
ductal carcinoma in situ |
非浸潤性乳管癌 |
DFI |
disease‒free interval |
無病生存期間 |
DFS |
disease‒free survival |
無病生存期間,無病生存率 |
EBCTCG |
Early Breast Cancer Trialists’ Collaborative Group |
|
EBM |
evidence-based medicine |
根拠に基づく医療 |
ECOG |
Eastern Cooperative Oncology Group |
|
EFS |
event‒free survival |
無イベント生存率 |
EIC |
extensive intraductal component |
広範な乳管内進展 |
EMLA |
eutectic mixture of local anesthetics |
|
EORTC |
European Organization for Research and Treatment of Cancer |
|
EORTC QLQ |
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire |
|
ER |
estrogen receptor |
エストロゲン受容体 |
FACT |
Functional Assessment of Cancer Therapy |
|
FDA |
Food and Drug Administration |
米国食品医薬品局 |
FSH |
follicle stimulating hormone |
卵胞(濾胞)刺激ホルモン |
G―CSF |
granulocyte―colony stimulating factor |
顆粒球コロニー刺激因子 |
GPA |
graded prognostic assessment |
|
GTV |
gross tumor volume |
肉眼的腫瘍体積 |
HER2 |
human epidermal growth factor receptor type 2 |
ヒト上皮増殖因子受容体2型 |
HR |
hazard ratio |
ハザード比 |
HRD |
homologous recombination deficiency |
相同組み換え修復不全 |
IBCSG |
International Breast Cancer Study Group |
|
ICG |
indocyanine green |
インドシアニングリーン |
IDFS |
invasive disease‒free survival |
浸潤癌の無病生存期間 |
IHC |
immunohistochemical staining |
免疫組織化学的方法 |
IMRT |
intensity modulated radiation therapy |
強度変調放射線治療 |
IPC |
intermittent pneumatic compression |
間歇的空気圧迫療法 |
ITC |
isolated tumor cells |
遊離腫瘍細胞 |
JCOG |
Japan Clinical Oncology Group |
日本臨床腫瘍研究グループ |
LLLT |
low level laser therapy |
低出力レーザー療法 |
LVEF |
left ventricular ejection fraction |
左室駆出率 |
NAC |
neoadjuvant chemotherapy |
術前化学療法 |
NCCAM |
National Center for Complementary and Alternative Medicine |
米国国立代替医療センター |
NCCN |
National Comprehensive Cancer Network |
全米総合がん情報ネットワーク |
NCI |
National Cancer Institute |
米国国立癌研究所 |
NSABP |
National Surgical Adjuvant Breast and Bowel Project |
|
NSAIDs |
non―steroidal anti―inflammatory drugs |
非ステロイド消炎鎮痛薬 |
N―SAS BC |
National Surgical Adjuvant Study of Breast Cancer |
|
NSM |
nipple―sparing mastectomy |
乳頭温存乳房全切除術 |
OBS |
oncoplastic breast surgery |
乳房オンコプラスティックサージャリー |
ONJ |
osteonecrosis of the jaw |
顎骨壊死 |
OR |
odds ratio |
オッズ比 |
ORR |
overall response rate |
全奏効割合,全奏効率 |
OS |
overall survival |
全生存期間,全生存率 |
PARP |
poly(ADP―ribose)polymerase |
ポリADPリボースポリメラーゼ |
pCR |
pathological complete response |
病理学的完全奏効 |
PD |
progressive disease |
進行 |
PFS |
progression free survival |
無増悪生存期間,無増悪生存率 |
PgR |
progesterone receptor |
プロゲステロン受容体 |
PMDA |
Pharmaceutical and Medical Devices Agency |
医薬品医療機器総合機構 |
PMPS |
postmastectomy pain syndrome |
乳房切除後疼痛症候群 |
PMRT |
postmastectomy radiation therapy |
乳房切除術後放射線療法 |
PPS |
post‒progression survival |
初回治療後の増悪後の生存期間 |
PS |
performance status |
パフォーマンスステータス |
PTV |
planning target volume |
計画標的体積 |
QOL |
quality of life |
生活の質 |
QOL‒ACD |
Quality of Life Questionnaire for Cancer Patients Targeted with American Drugs |
|
RANKL |
receptor activator of nuclear factor κ―B ligand |
|
RCT |
randomized controlled trial |
ランダム化比較試験 |
RFA |
radiofrequency ablation |
ラジオ波熱凝固療法 |
RFS |
relapse―free survival,recurrence―free survival |
無再発生存期間,無再発生存率 |
RI |
radioisotope |
ラジオアイソトープ |
RR |
rate ratio |
レート比 |
RR |
risk ratio |
リスク比 |
RS |
recurrence score |
|
RTOG |
Radiation Therapy Oncology Group |
米国腫瘍放射線治療グループ |
RT‒PCR |
reverse transcription polymerase chain reaction |
|
SD |
stable disease |
|
SE |
standard error |
標準誤差 |
SEER |
Surveillance, Epidemiology and End Results |
|
SERM |
selective estrogen receptor modulator |
選択的エストロゲン受容体モジュレーター |
SLE |
systemic lupus erythematosus |
全身性エリテマトーデス |
SLN |
sentinel lymph node |
センチネルリンパ節 |
SNB |
sentinel node biopsy |
センチネルリンパ節生検 |
SRE |
skeletal―related event |
骨関連事象 |
SRS |
stereotactic radiosurgery |
定位手術的照射 |
SRT |
stereotactic radiotherapy |
定位[的]放射線治療 |
SSI |
surgical site infection |
手術部位感染 |
SSM |
skin―sparing mastectomy |
皮膚温存乳房全切除術 |
SSO |
Society of Surgical Oncology |
|
SSRI |
selective serotonin reuptake inhibitor |
選択的セロトニン再取込み阻害薬 |
STI |
stereotactic irradiation |
定位放射線照射 |
SWOG |
Southwest Oncology Group |
|
TE |
tissue expander |
組織拡張器 |
TNBC |
triple negative breast cancer |
トリプルネガティブ乳癌 |
TPC |
treatment of physician’s choice |
|
TTF |
time to treatment failure |
治療成功期間 |
TTP |
time to progression |
無増悪期間,病勢進行までの期間 |
VATS |
video―assisted thoracic surgery |
胸腔鏡手術 |
VEGF |
vascular endothelial growth factor |
血管内皮増殖因子 |
VNPI |
Van Nuys prognostic index |
|
WHO |
World Health Organization |
世界保健機関 |
YAM |
young adult mean |
若年成人平均値 |